Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey

Figures & data

Table 1 Results by Mode of Practice (Hospital and Mixed Practice/Private Practice)

Study Population	Hospital/Mixed Practice (n=161)	Private Practice (n=93)	Chi Square
Prescription of methotrexate	93.3% (n=153/161)	90.32% (n=84/161)	NS
Average length of service (years)	18.2	19.9	p=0.02
Analyse population	Hospital/mixed practice (n=153)	Private practice (n=84)	Chi square
Average length of service (years)	18.2	19.9	p=0.02
Systemic treatment line in which methotrexate is prescribed
1st line	69.93% (n=107)	33.3% (n=28)	p=0.001
2nd line	23.5% (n=36/)	39.3% (n=33)
3rd line	6.5%(n=10)	25% (n=21)
4th line	0%(n=0)	2.4% (n=2)
Carrying out a test dose at initiation	19.6% (n=30)	19% (n=16)	NS
How methotrexate is administered
Per os	52.2%	59.4%	NS
Subcutaneous pen	40%	29%	p=0.007
Subcutaneous syringe	7.4%	11%	NS
Intramuscular	0.3%	0.6%	NS
Percentage of patients who are autonomous in carrying out injections	69.4%	58.2%	p= 0.04
Initiation dosage of methotrexate
< 15 mg/week	21%(n=32)	52.4%(n=40)	p<0.001
≥ 15 mg/week	79%(n=121)	47.6%(n=44)
Time frame for evaluating the effectiveness of methotrexate
< 6 weeks	4.6%(n=7)	16.7%(n=14)	p< 0.003
6 to 8 weeks	11.1%(n=17)	15.4% (n=13)
≥10 weeks	84.3%(n=129)	67.9%(n=57)
Dose adjustment level used
2.5 mg/week	47.1%(n=72)	69% (n=58)	p< 0.001
5 mg/week	50.3%(n=77)	26.2%(n=22)
Others	2.6% (n=4)	4.8%(n=4)
Reasons for switching from an oral to an injectable form	91%	76%	p< 0.001
Poor tolerance	43.9%(n=61)	57.8%(n=37)	p=0.004
Lack of efficacy	35.2%(n=49)	34.4%(n=22)
Lack of compliance	20.9%(n=29)	7.8%(n=5)
Concomitant prescription of folic acid	98.9%	98.3%	NS
Prescription test for the evaluation of hepatic fibrosis	77.8%(n=119)	82.1%(n=69)	p< 0.001

Abbreviation: NS, not significant.